Patent Number: 8,067,247

Title: Use of anti-CD100 antibodies for the treatment of inflammatory disorders affecting the central or peripheral nervous system

Abstract: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.

Inventors: Belin; Marie-Francoise (Lyons, FR), Giraudon; Pascale (Lyons, FR), Boumsell; Laurence (Paris, FR), Bensussan; Armand (Paris, FR)

Assignee: Institut National de la Sante Et de la Recherche Medicale (INSERM)

International Classification: G01N 33/53 (20060101); C07K 16/00 (20060101); A61K 39/00 (20060101); A61K 39/395 (20060101); C12P 21/08 (20060101)

Expiration Date: 2020-11-29 0:00:00